Pterostilbene
Phase 2Biologic
Pterostilbene is one of 74 biologic programs targeting Oxidative Stress. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
258 competitors in Endometrial Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Femara
NovartisPhase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Adriamycin
PfizerPhase 3
Lynparza
AstraZenecaPhase 3
Lenvima
EisaiPhase 3
Tecentriq
RochePhase 3
Trodelvy
GileadPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Endometrial Cancer1 trial
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
Active, not recruiting·—·Phase 2·NCT03671811·44 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pterostilbene. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details